Compare INLX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | BCTX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 26.6M |
| IPO Year | 2013 | 2025 |
| Metric | INLX | BCTX |
|---|---|---|
| Price | $5.38 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 1.3K | ★ 119.4K |
| Earning Date | 05-14-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,336.00 | N/A |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.21 | $0.63 |
| 52 Week High | $12.48 | $14.68 |
| Indicator | INLX | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | N/A |
| Support Level | $5.45 | N/A |
| Resistance Level | $7.87 | N/A |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.82 | 0.00 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.